All In Biotech

Drug Trial Radar · NCT03575351

A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas

A Global Randomized Multicenter Phase 3 Trial of JCAR017 Compared to Standard of Care in Adult Subjects With High-risk, Second-line, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas (TRANSFORM).

Last checked: Nov 19, 2026Latest source record: Aug 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 184 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

184

Actual

Start

Oct 23, 2018

Primary completion

Oct 23, 2023

Study completion Oct 23, 2023

Sponsor

Lead sponsor
CelgeneBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Jul 2, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will be conducted in compliance with the International Council for Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory requirements. This is a randomized, open-label, parallel-group, multi-center trial in adult subjects with Relapsed or refractory (R/R) aggressive Non-Hodgkin lymphoma (NHL) to compare safety and efficacy between the standard of care (SOC) strategy versus JCAR017 (also known as lisocabtagene maraleucel or liso-cel). Subjects will be randomized to either receive SOC (Arm A) or to receive JCAR017 (Arm B). All subjects randomized to Arm A will receive Standard of care (SOC) salvage therapy (R-DHAP, RICE or R-GDP) as per physician's choice before proceeding to High dose chemotherapy (HDCT) and Hematopoietic stem cell transplant (HSCT). Subjects from Arm A may be allowed to cross over and receive JCAR017 upon confirmation of an EFS event. Subjects randomized to Arm B will receive Lymphodepleting (LD) chemotherapy followed by JCAR017 infusion.

Conditions

  • Lymphoma, Non-Hodgkin

Interventions

  • Standard of CareDrug

    Standard of Care

  • JCAR017Genetic

    JCAR017

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Event-free Survival (EFS) Per Independent Review Committee (IRC)Time frame: From randomization to death from any cause, PD, failure to achieve CR or PR by 9 weeks post randomization, or start of new antineoplastic therapy due to efficacy concerns, whichever occurs first (Up to 36 months)

Locations

54 sites in 12 countries. Site status is shown where the registry gives one.

  • Local Institution - 129

    Scottsdale, Arizona

  • Local Institution - 116

    Scottsdale, Arizona

  • Local Institution - 115

    San Francisco, California

  • Local Institution - 106

    Aurora, Colorado

  • Mayo Clinic - Jacksonville

    Jacksonville, Florida

  • Local Institution - 126

    Tampa, Florida

  • Local Institution - 108

    Atlanta, Georgia

  • Local Institution - 107

    Atlanta, Georgia

  • Local Institution - 122

    Chicago, Illinois

  • Loyola University Medical Center Cardinal Bernardin Cancer Center

    Maywood, Illinois

  • Local Institution - 102

    Boston, Massachusetts

  • Local Institution - 104

    Boston, Massachusetts

  • Local Institution - 120

    Ann Arbor, Michigan

  • Local Institution - 119

    Detroit, Michigan

  • Local Institution - 112

    Minneapolis, Minnesota

  • Local Institution - 103

    Rochester, Minnesota

  • Local Institution - 100

    Omaha, Nebraska

  • Local Institution - 121

    Hackensack, New Jersey

  • Local Institution - 111

    Buffalo, New York

  • Local Institution - 117

    New York, New York

  • Local Institution - 125

    Charlotte, North Carolina

  • Local Institution - 127

    Oklahoma City, Oklahoma

  • Local Institution - 101

    Portland, Oregon

  • Local Institution - 123

    Pittsburgh, Pennsylvania

  • Local Institution - 109

    Dallas, Texas

  • Local Institution - 124

    Houston, Texas

  • Local Institution - 114

    Richmond, Virginia

  • Local Institution - 110

    Seattle, Washington

  • Local Institution - 350

    Ghent, Belgium

  • Local Institution - UNK 25

    Helsinki, Finland

  • Local Institution - 401

    Lille, France

  • Local Institution - 400

    Marseille, France

  • Local Institution - 403

    Pierre-Bénite, France

  • Local Institution - 402

    Villejuif, France

  • Local Institution - 451

    Berlin, Germany

  • Local Institution - 450

    Cologne, Germany

  • Local Institution - 452

    Hamburg, Germany

  • Local Institution - 453

    München, Germany

  • Local Institution - 454

    Münster, Germany

  • Local Institution - 455

    Dresden, Saxony, Germany

Showing 40 of 54 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.